The Oncologist

02/25/2026

The QuICC trial tested a quadruple regimen in mismatch repair–proficient metastatic **alCancer, showing that combining multiple immune agents can elicit clinical activity in tumors traditionally resistant to immunotherapy.
https://doi.org/10.1093/oncolo/oyag008

02/23/2026

Network meta-analysis in RAS wild-type metastatic **alCancer: triplet chemo + anti-EGFR improves response vs chemo alone, but no clear survival advantage over other targeted combinations. Careful patient selection remains key due to increased toxicity.
https://doi.org/10.1093/oncolo/oyag011

02/20/2026

In this largest real-world cohort of metastatic to date, the clinical benefit and manageable safety of sacituzumab govitecan seen in the ASCENT trial was confirmed in routine practice. Notably, poor performance status and liver metastases predicted inferior outcomes.

AbstractBackground. Sacituzumab govitecan (SG), an antibody–drug conjugate targeting TROP-2, demonstrated superior efficacy over standard chemotherapy in h

02/19/2026

Survey: Community MDs prioritize overall survival & quality of life in choosing third-line drugs for metastatic **alCancer. Most favored trifluridine-tipiracil+bevacizumab. Fatigue, neutropenia, & hand-foot syndrome were top concerns influencing choices.

AbstractBackground. Colore**al cancer (CRC) is the second leading cause of cancer-related death worldwide, with increasing incidence in the US. Improvement

02/17/2026

The role of patient navigation programs in early cancer care in Mexico: a multi-case qualitative study
https://doi.org/10.1093/oncolo/oyaf314

02/13/2026

Adjuvant chemotherapy improved survival for patients with an LNR below 11%, while it provided no benefit for those with higher LNRs. An LNR threshold of 11% can personalize treatment, identifying those who may need chemotherapy or more intensive treatments like chemoradiotherapy.

AbstractBackground. The lymph node ratio (LNR) has emerged as an important prognostic factor in various cancers, including esophageal squamous cell carcino

02/12/2026

FDA GI cancer drug approvals rely on pathways, surrogate endpoints, and trials. From 2006–2025, survival gains were modest 2.1 mo, and few met substantial clinical , raising concerns about meaningful patient outcomes
https://doi.org/10.1093/oncolo/oyaf381

02/11/2026

A retrospective look at registry shows patient choice of oncologist in is driven by and , not age, gender, or . disease and strong reduce second opinions

Abstract. Choice of oncologist by patients with pancreatic cancer is a complex personal decision. We conducted a retrospective analysis of the Pancreatic C

02/10/2026

Advanced ampullary carcinoma is rare and lacks guidelines. In trials, had modest outcomes 24% ~8 mo, ~12 mo similar to other . This analysis supports as standard but underscores need for molecularly guided, collaborative trials

Abstract. Ampullary carcinoma (AC) is a rare malignancy. It is often classified within biliary tract cancers (BTC) but lacks dedicated treatment guidelines

02/09/2026

Analysis of 1,935 and pancreatic shows older 👴 and male *x lead to lower , tumor ,🧬 and immune profiles. Distinct and *x specific patterns may inform future and care

AbstractPurpose. Age and s*x are known to influence outcomes in neuroendocrine neoplasms (NENs), yet their molecular determinants remain poorly defined. We

02/06/2026

In stage II/III **al 💉☢️, adjuvant or showed no or benefit over 5-FU alone. Early closure limited power. Outcomes favor approaches.
https://doi.org/10.1093/oncolo/oyaf416

02/05/2026

This study utilizes interviews with and . Metastatic cancer causes heavy symptom burden 🥴😵‍💫with major emotional and functional impacts 😰😭. Current for are lacking, disease specific are needed
https://doi.org/10.1093/oncolo/oyaf427